Compare · BLI vs DFTX
BLI vs DFTX
Side-by-side comparison of Berkeley Lights Inc. (BLI) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLI and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 10.2x BLI ($591.8M).
- DFTX has hit the wire 15 times in the past 4 weeks while BLI has been quiet.
- BLI has more recent analyst coverage (13 ratings vs 7 for DFTX).
- Company
- Berkeley Lights Inc.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $591.8M
- $6.02B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 15
- Recent ratings
- 13
- 7
BLI
Berkeley Lights Inc.
Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.
Latest BLI
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)
- SEC Form 15-12G filed by Berkeley Lights Inc.
- Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hopfield Jessica returned 105,207 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Joshi Mehul returned 65,013 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hobbs Eric returned 244,816 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Moritz Michael J returned 1,451,925 shares to the company (SEC Form 4)
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder